Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02788773
Title Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer
Recruitment Active, not recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors Canadian Cancer Trials Group
Indications

prostate adenocarcinoma

Therapies

Durvalumab + Tremelimumab

Durvalumab

Age Groups: senior | adult
Covered Countries CAN


No variant requirements are available.